Imported eosinophilic fever with myositis : A diagnostic challenge
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Travel medicine and infectious disease - 24(2018) vom: 30. Juli, Seite 16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Camprubí, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albendazole |
|---|
| Anmerkungen: |
Date Completed 21.11.2018 Date Revised 21.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tmaid.2018.05.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28448458X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28448458X | ||
| 003 | DE-627 | ||
| 005 | 20231225043324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tmaid.2018.05.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0948.xml |
| 035 | |a (DE-627)NLM28448458X | ||
| 035 | |a (NLM)29802894 | ||
| 035 | |a (PII)S1477-8939(18)30102-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Camprubí, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imported eosinophilic fever with myositis |b A diagnostic challenge |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2018 | ||
| 500 | |a Date Revised 21.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antiprotozoal Agents |2 NLM | |
| 650 | 7 | |a Drinking Water |2 NLM | |
| 650 | 7 | |a L-Lactate Dehydrogenase |2 NLM | |
| 650 | 7 | |a EC 1.1.1.27 |2 NLM | |
| 650 | 7 | |a Transaminases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.- |2 NLM | |
| 650 | 7 | |a Albendazole |2 NLM | |
| 650 | 7 | |a F4216019LN |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Rodriguez-Valero, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Losada, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Grau-Junyent, Josep Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Jose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 24(2018) vom: 30. Juli, Seite 16 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2018 |g day:30 |g month:07 |g pages:16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2018.05.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2018 |b 30 |c 07 |h 16 | ||